Clinical trials: Bladder Tumors
Muscle-Invasive Bladder Carcinoma
Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer
In this phase II study, eligible patients will be treated with maximal tumor resection and then started treatment within 8 weeks. Chemotherapy, Nivolumab and radiotherapy (RT) will be started on day one.
- Trial name
- CNN-BC (NCT05203913)
- Testing
- Nivolumab, Nab paclitaxel, Cisplatin
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Bladder Carcinoma, Prostate Tumor
Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device
The REMOVE study was an open-label, multicenter validation study on the removal of EpCAM-positive tumor cells from blood collected during tumor surgery using the CATUVAB Kit.
- Conditions
- Bladder Carcinoma, Prostate Tumor, Gallbladder Carcinoma, Endometrial Carcinoma
- Trial name
- REMOVE (NCT06789224)
- Testing
- CATUVAB
- Where
- 6 sites in Germany
- Volunteers
- 136 people
- Sponsor
- Lindis Bloodcare GmbH
Survivors of Childhood Cancer, Bladder Dysfunction
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
The over-arching aim of this study is to evaluate the effects of two specific anti-cancer chemotherapies, vincristine and doxorubicin, on bladder function and urine composition.
- Trial name
- NCT04993859
- Testing
- Non-invasive Urodynamic Test (niUDS), Urinary proteomic screen, Dysfunctional Voiding Symptom Score Survey (DVSS)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- University of Colorado, Denver
Bladder (Urothelial, Transitional Cell) Cancer, Non Muscle Invasive Bladder Cancer
Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
Patients with extensive transurethrally unresectable very-high-risk non-muscle-invasive bladder cancer (NMIBC) may achieve a tumor-free status after systemic immunotherapy-based bladder-sparing treatment combined with…
- Trial name
- NCT07625527
- Testing
- Active Surveillance, PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy
- Where
- 4 sites in China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Second Hospital
Neoplasm of Lateral Wall of Urinary Bladder
Safety Study of Bipolar Versus Monopolar Transurethral Resection of Bladder Tumors
This is a single-center, prospective, randomized, controlled trial comparing two established transurethral electrical resection methods of urinary bladder tumors regarding their risk of stimulating the obturator nerve.
- Trial name
- NCT01446822
- Testing
- Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius), Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)
- Where
- Switzerland
- Volunteers
- 44 people
- Sponsor
- Daniel Stephan Engeler
Prostate Cancer, Bladder Cancer
Decipher Genomics Resource for Intelligent Discovery
To prospectively evaluate the utility of genomic expression data and whole slide digital pathology image data as a tool to better characterize the tumors of individual patients, and to understand how genomic and histologic…
- Conditions
- Prostate Cancer, Bladder Cancer, Renal Cancer
- Trial name
- GRID® (NCT02609269)
- Testing
- Decipher Cancer Classifier
- Volunteers
- 1,000,000 people
- Sponsor
- GenomeDx Biosciences Corp
Head and Neck Cancer, Melanoma
Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study
This is an open-label, dose escalation study of the safety and tolerability of Recombinant oncolytic adenovirus L-IFN injection（YSCH-01） when administered via intratumoral injection in patients with advanced solid tumors.
- Conditions
- Head and Neck Cancer, Melanoma, Breast Cancer, Bladder Cancer
- Trial name
- YSCH-01 (NCT05180851)
- Testing
- Recombinant L-IFN adenovirus injection
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Fengxian District Central Hospital
Prostate Cancer, Bladder Cancer
A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer
Radical radiation therapy for prostate cancer is a common treatment that has shown to improve clinical outcomes in a post-operative setting.
- Trial name
- ARTGU (NCT03909893)
- Testing
- Adaptive Radiation Therapy
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Urinary Bladder Neoplasms, Transurethral Resection
Ultrasound-Guided ONB for Transurethral Procedures - Interadductor Approach
Obturator nerve block is an effective method to prevent adductor muscles contraction during transurethral resection of bladder tumour localized on the lateral wall.
- Conditions
- Urinary Bladder Neoplasms, Transurethral Resection, Nerve Block
- Trial name
- NCT02696733
- Testing
- Ultrasound, lidocaine 2%, 0.9% Natrium Chloratum with a 2nd generation cephalosporin
- Where
- 2 sites in Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Warsaw
Bladder Cancer
Measuring Urinary Nano Particles and Metallic Compounds in TCC Patients
In many of urothelial carcinoma patients, one does not find common risk factors such as smoking. The medical center is located in an industrial city with known air and water pollution.
- Trial name
- NCT02811952
- Testing
- without intervention
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Carmel Medical Center
Urothelial Cancer, Bladder Cancer
Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
The main purpose of this study is to look at the cancer-free survival at two years of subjects with high risk upper tract urothelial cancer when treated with the combination of two chemotherapy drugs called Gemcitabine and…
- Trial name
- NCT01663285
- Testing
- Neoadjuvant Cisplatin and Gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan Rogel Cancer Center
Non-Muscle-Invasive Bladder Cancer (NMIBC)
A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy
This is an open label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of RAG-01 in patients with NMIBC who have failed BCG therapy.
- Trial name
- NCT06351904
- Testing
- RAG-01
- Where
- 3 sites in Australia
- Volunteers
- 72 people
- Sponsor
- Ractigen Therapeutics.
Biliary Tract Cancer
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors
The main purpose of this study is to determine if XL119 is more effective than the combination of 5-fluorouracil (5FU) and leucovorin (LV) in prolonging the survival of subjects with advanced biliary tumors.
- Trial name
- NCT00090025
- Testing
- becatecarin, 5-Fluorouracil Plus Leucovorin
- Where
- 59 sites in United States, Belgium and 9 more
- Volunteers
- 248 people
- Sponsor
- Helsinn Healthcare SA
Urothelial Cancer, Bladder Cancer
Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer
This study will involve subjects who have advanced urothelial cancer who are platinum refractory (platinum based chemotherapies that are not effective in treating the cancer), and who are over-expressing EGFR and/or HER2, or do…
- Trial name
- NCT01700010
- Testing
- Lapatinib and Paclitaxel
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Chemotherapy Effect, Chemotherapeutic Toxicity
Lower Urinary Tract Symptoms After Intravesical Therapy
With this prospective, observational study, we would like to investigate the effect of instillation therapy using BCG or mitomycin C on short- and long-term irritative and obstructive lower urinary tract symptoms using validated…
- Conditions
- Chemotherapy Effect, Chemotherapeutic Toxicity, Lower Urinary Tract Symptoms, Overactive Bladder
- Trial name
- LUTSI (NCT05844059)
- Testing
- Validated questionnaires
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Bladder Cancer, Breast Cancer
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Picoplatin is a new platinum-based chemotherapy drug that has been studied in a variety of cancers. Phase 1 and 2 studies have demonstrated that picoplatin may be effective in patients whose cancer returns or does not improve…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastrointestinal Neoplasm
- Trial name
- NCT00465725
- Testing
- Picoplatin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Poniard Pharmaceuticals
Tumor
A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types
- Trial name
- CheckMate 76U (NCT04311710)
- Testing
- ipilimumab, nivolumab, ENHANZE (rHuPH20)
- Where
- 6 sites in United States, Italy and 1 more
- Volunteers
- 21 people
- Sponsor
- Bristol-Myers Squibb
Bladder Cancer
Enhanced Recovery After Surgery (ERAS) for Ambulatory TURBT
This is a single-center, randomized-controlled trial to investigate the effectiveness of an ERAS protocol compared to usual care in patients with bladder cancer undergoing ambulatory TURBT.
- Trial name
- NCT05905276
- Testing
- ERAS Protocol, Standard of Care
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Johns Hopkins University
Bladder Cancer
Bladder Tumor Biopsy Study to Improve Preoperative Determination of Stage and Grade
To assess whether the addition of a bladder tumor biopsy improves the level of agreement between the pretreatment endoscopic impression and the final postoperative pathology determination of stage and grade in non-muscle-invasive…
- Trial name
- NCT02992990
- Testing
- Bladder tumor biopsy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Baylor College of Medicine
Bladder Carcinoma
Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy
This randomized phase II/III trial studies gabapentin in reducing the need for pain medication in patients with bladder cancer undergoing surgery to remove the bladder and nearby tissue and organs.
- Trial name
- NCT02355886
- Testing
- Gabapentin, Questionnaire Administration
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Washington
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.